皮膚疾患市場動向：2007〜2012、2017、2022年

Abstract

Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness increases in Western countries, botulinum toxin and other cosmetic treatments become more and more popular.

The treatment of dermatological disorders are often a cause for concern. Users are keen to benefit from the treatments, often to the point were they overlook possible health concerns. In 2006 September, the FDA launched the iPledge program to prevent birth defects caused by use of isotretinoin during pregnancies. In addition, Roaccutane, an isotretinoin agent for acne, might disrupts serotonin to cause a range of aggression, anger and sleep, according to the study from University of Bath in the UK - this is not the first time studies have shown Roaccutane to be dangerous to some.

This skin disorder report contains:

• The prevalence of skin disorder and the number of cosmetic procedures: It includes the prevalence in the seven major markets.
• The current treatments and future potential treatments as well as drug delivery technologies.
• Current market analysis, including topical and systemic dermatological treatments. The analysis contains the strategic analysis of sales performance, market share and sales forecast to 2012, 2017 and 2022
• Key players analysis, including the analysis of the product portfolio, R&D and the analyses of strategies.
• Porter-Five-Forces Analysis and SWOT analysis to offer the understanding of the strategic issues will impact on dermatological market

Key Market for the Future

Visiongain predicts that the retail market for dermatological treatments will continue to show significant growth for what is an already large market. Corticosteroid agents will still be the main sales drivers to dermatological market whilst botulinum toxin and other cosmetic treatments will be more significant during the forecast period.

Why You Should Buy This Report

• Dermatological treatments is a important therapeutic area which have significant impact to most population globally
• Which treatments are the most efficient for acne, psoriasis and other dermatological conditions? Does any safety concern occur on those treatments? This report will not only answer those questions but also give you the comprehensive view on the patients' perception for those treatments.
• Corticosteroid agents are widely used on skin disorder due to its potent effect. This report will help you top assess just what impact that this is likely to have.
• Cosmetic procedures become more significant in the recent years, including the treatments of botulinum toxin and hyaluronic acid. Visiongain will tell the market performance and impact of those products.
• Visiongain has taken the latest available financial and prevalence statistics with forecast revenue figures for each dermatological treatment, all the leading products and blockbusters to 2012 or 2022.
• The report contains strategic analysis of the pipeline, in addition, the current market and strategies analysis for key players.

Why You Must Buy This Report?

This report features news, insights, the latest developments and an in depth survey of the pain market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company ' the edge' on your competitors. You can not afford to be without this latest report from visiongain.

Unique benefits to you when you order this report

• You can access your report whichever country you are in without using harddrive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Table of Contents

Chapter 1 Executive Summary

• 1.1 Dermatological Market Overview
• 1.2 Aims, Scope and Format of the Report
• 1.3 Structure of the Report

Chapter 2 Introduction of Overall Skin Diseases and Dermatological Treatments

• 2.1 The Structure of the Skin
  • 2.1.1 Hair
  • 2.1.2 Swear and Sebaceous Glands
  • 2.1.3 Nails
• 2.2 The physiological Role of Skin
  • 2.2.1 Protection
  • 2.2.2 Sensory Perception
  • 2.2.3 Storage
  • 2.2.4 Absorption/Vitamin D Formulation
  • 2.2.5 Temperature Regulation
• 2.3 Differences in Skin Due to Gender
• 2.4 The effects of Age on Skin Structure
• 2.5 Inflammation and Histamine Release
• 2.6 Common Skin Problems
  • 2.6.1 Blackheads
  • 2.6.2 Boils
  • 2.6.3 Cold Sores
  • 2.6.4 Freckles
  • 2.6.5 Moles
  • 2.6.6 Pimples
  • 2.6.7 Warts
• 2.7 Common Skin Treatments
  • 2.7.1 Topical Preparations
    • 2.7.1.1 Creams and Semisolid Emulsions
    • 2.7.1.2 Ointments
    • 2.7.1.3 Lotions
    • 2.7.1.4 Solutions
    • 2.7.1.5 Occlusive Therapy
  • 2.7.2 Cleansing Agents
  • 2.7.3 Protectant Powders and Hydrophilic Polymers
  • 2.7.4 Anti-Infective Agents
  • 2.7.5 Anti-Inflammatory Agents

Chapter 3 Treatments and Dermatological Market Analysis for Acne

• 3.1 The Introduction of Acne
  • 3.1.1 Pathogenesis and Causations
    • 3.1.1.1Pathogenesis
    • 3.1.1.2 Causations
  • 3.1.2 The Diagnosis of Acne
• 3.2 Symptoms Definitions
  • 3.2.1 Comedone
  • 3.2.2 Papule
  • 3.2.3 Pustule
  • 3.2.4 Macule
  • 3.2.5 Nodule
  • 3.2.6 Cyst
• 3.3 Patient analysis
  • 3.3.1 Women and Acne
  • 3.3.2 Social Impact of Acne
• 3.4 Treatments
  • 3.4.1 Topical Pharmaceutical Treatments
    • 3.4.1.1 Topical Antibiotics
    • 3.4.1.2 Azlaic Acid
    • 3.4.1.3 Benzoyl Peroxide
    • 3.4.1.4 Sulfonamide (Sulfacet-R)
    • 3.4.1.5 Topical Retinoids
  • 3.4.2 Oral Pharmaceutical Treatments
    • 3.4.2.1 Oral Retinoids
    • 3.4.2.2 Oral Antibiotics
    • 3.4.2.3 The Estrogen (cyproterone/ethinylestradiol)
    • 3.4.2.4 Corticosteroids
    • 3.4.2.5 Other Hormonal Therapies
  • 3.4.3 Other Treatments for Acne
• 3.5 Acne World Market Outlook
  • 3.5.1 Current Events
  • 3.5.2 Global Market Analysis
  • 3.5.3 Topical Acne Treatments Market Analysis
  • 3.5.4 Top Oral Acne Treatments Analysis
  • 3.5.5 Sales Forecasts
    • 3.5.5.1 Topical Acne Treatments
    • 3.5.5.2 Oral Acne Treatments
    • 3.5.5.3 Conclusion

Chapter 4 Treatments and Dermatological Market Analysis for Psoriasis

• 4.1 The Introduction of Psoriasis
  • 4.1.1 Causations
  • 4.1.2 Symptoms
  • 4.1.3 Type
  • 4.1.4 Complications
• 4.2 Patient analysis
  • 4.2.1 Prevalence
• 4.3 Treatments
  • 4.3.1 Topical Agents
    • 4.3.1.1 Anthralin
    • 4.3.1.2 Coal tar
    • 4.3.1.3 Retinoids
    • 4.3.1.4 Vitamin D3 (Calcipotripol)
    • 4.3.1.5 Topical corticosteroids (steroids)
    • 4.3.1.6 Emollients4.3.1.7 Keratolytics 4.3.1.8 Patients' Preference for Topical Agents
  • 4.3.2 Systemic Treatments
    • 4.3.2.1 Oral Retinoid Systemic Agents
    • 4.3.2.2 Biologic Agents
    • 4.3.2.3 Phototherapy and Photochemotherapy
• 4.4 Psoriasis/ Pruritus World Market Outlook
  • 4.4.1 Current Global Psoriasis Market
  • 4.4.2 Leading Brands Analysis
    • 4.4.2.1 Dovonex/Daivonex/Daivobet/Taclonex (calciportiene/betamethasone)
    • 4.4.2.2 Raptiva
    • 4.4.2.3 Zorac (tazarotene)
    • 4.4.2.4 Soriatane and Neotigason
  • 4.4.3 Sales Forecasts

Chapter 5 Treatments and Dermatological Market Analysis for Skin Infection

• 5.1 The Introduction of Skin Infection
  • 5.1.1 Bacterial Skin Infections
  • 5.1.2 Bacteria-infected Patients Analysis
• 5.2 Fungal Skin Infections
  • 5.2.1 Dermatophyte Infections
  • 5.2.2 Fungal-infected Patient Analysis
  • 5.2.3 Treatments for fungal infections
    • 5.2.3.1 Ringworm Treatments
    • 5.2.3.2 Tinea Corporis Treatments
    • 5.2.3.3 Tinea Pedis Treatments
    • 5.2.3.4 Tinea Unguium Treatments
    • 5.2.3.5 Tinea Capitis Treatments
• 5.3 Viral Infections
  • 5.3.1 Herpes Simplex
  • 5.3.2 Chicken Pox (Varicella)
  • 5.3.3 Herpes Zpster
  • 5.3.4 Warts (Verrucae)
  • 5.3.5 Viral-infected Patients Analysis
  • 5.3.6 Treatments
• 5.4 Skin Parasites
  • 5.4.1 Scabies
  • 5.4.2 Lice
• 5.5 World Market Outlook for Dermatological-Infective Treatments
  • 5.5.1 Current Market Analysis
  • 5.5.2 Key Brands Analysis
    • 5.5.2.1 Anti-Vrial Treatments
    • 5.5.2.2 Anti-Fungal Treatments
    • 5.5.2.3 Anti-Bacterial Treatments
  • 5.5.3 Sales Forecasts

Chapter 6 Dermatitis, Rosacea, Urticaria and Alopecia

• 6.1 Introduction of Dermatitis
  • 6.1.1 Atopic dermatitis
  • 6.1.2 Contact dermatitis
  • 6.1.3 Seborrheic dermatitis
  • 6.1.4 Dermatitis Patient analysis
• 6.2 The Introduction of Rosacea
  • 6.2.1 Symptoms
  • 6.2.2 Types and Causations
  • 6.2.3 Patient analysis
• 6.3 The Introduction of Urticaria
  • 6.3.1 Acute Urticaria
  • 6.3.2 Chronic Urticaria
  • 6.3.3 Physical Urticaria
  • 6.3.4 Dermatographic Urticaria
  • 6.3.5 Patient Analysis
• 6.4 Introduction of Alopecia
  • 6.4.1 Alopecia Areata
  • 6.4.2 Androgenic Alopecia
  • 6.4.3 Telogen effluvium
  • 6.4.4 Trichotillomania and traction alopecia
  • 6.4.5 Prevalence of Alopecia
• 6.5 Treatments for Dermatitis, Rosacea and Urticaria
  • 6.5.1 Treatments of Dermatitis
  • 6.5.2 Treatments for Rosacea
    • 6.5.2.1 Topical Treatments
    • 6.5.2.2 Systemic Treatments for Rosacea
    • 6.5.2.3 Conclusion
  • 6.5.3 Treatments for Urticaria
  • 6.5.4 Treatments for Alopecia
    • 6.5.4.1 Alopecia Areata
    • 6.5.4.2 Androgenic Alopecia
    • 6.5.4.3 Telogen Effluvium
• 6.6 Global Market Analysis for Dermatitis, Rosacea, Urticaria and Alopecia Treatment Market
  • 6.6.1 Corticosteroids
    • 6.6.1.1 Leading Brands Analysis
    • 6.6.1.2 Sales Forecasts
  • 6.6.2 Other Dermatologic Treatments Market
    • 6.6.2.1 Leading Brand Analysis
    • 6.6.2.2 Sales Forecasts

Chapter 7 Treatments and Dermatological Market Analysis for Aesthetic Dermatology

• 7.1 The Introduction of Aesthetic Dermatology
• 7.2 Surgical and Non-surgical Market
• 7.3 Expenditure
• 7.4 Treatments
  • 7.4.1 Superficial Chemical Peeling
  • 7.4.2 Dermabrasion
  • 7.4.3 Laser Skin Resurfacing
  • 7.4.4 Electrosurgical Resurfacing
  • 7.4.5 Superfluous Hair Removal
  • 7.4.6 Liposuction
  • 7.4.7 Surgery
  • 7.4.8 Soft-Tissue Augmentation/Dermal Fillers
    • 7.4.8.1 Collagen Injections
    • 7.4.8.2 Body Fat Transfer and Body Sculpturing
    • 7.4.8.3 Hyaluronic Acid Injections
  • 7.4.9 Topical Treatments
  • 7.4.10 Botulinum Toxin
• 7.5 Aesthetic Dermatology World Market Outlook
  • 7.5.1 Leading Product Analysis
  • 7.5.2 Sales Forecasts

Chapter 8 Key Player and Pipeline Analysis

• 8.1 Allergan
  • 8.1.1 Marketed Dermatological Product Portfolio
    • 8.1.1.1 Neuromodulator Product
    • 8.1.1.2 Skin Care Product Line
    • 8.1.1.3 Facial Aesthetics
    • 8.1.1.4 Other Aesthetics Products
  • 8.1.2 R&D Pipeline Analysis
  • 8.1.3 Strategic Analysis
  • 8.1.4 Conclusion
• 8.2 GlaxoSmithKilne
  • 8.2.1 Marketed Dermatological Product Portfolio
  • 8.2.2 R&D
  • 8.2.3 Strategic Analysis and Conclusion
• 8.3 Johnson&Johnson
  • 8.3.1 Marketed Dermatological Product Portfolio
  • 8.3.2 R&D Pipeline Analysis
  • 8.3.3 Strategic Analysis
• 8.4 L' Oreal
  • 8.4.1 Marketed Dermatological Product Portfolio
  • 8.4.2 Leading Brands Analysis
  • 8.4.3 Strategic Analysis
• 8.5 Leo Pharma
  • 8.5.1 Marketed Dermatological Product Portfolio
  • 8.5.2 R&D Pipeline Analysis
  • 8.5.3 Strategic Analysis
• 8.6 Novartis
  • 8.6.1 Marketed Dermatological Product Portfolio
  • 8.6.2 R&D Pipeline Analysis
  • 8.6.3 Strategic Analysis
• 8.7 Roche
  • 8.7.1 Marketed Dermatological Product Portfolio
  • 8.7.2 Strategic Analysis
• 8.8 Stiefel Laboratories
  • 8.8.1 Marketed Dermatological Product Portfolios
  • 8.8.2 R&D Pipeline Analysis
  • 8.8.3 Strategic Analysis
• 8.9 Bayer Schering Pharma
  • 8.9.1 Marketed Dermatological Product Portfolio
  • 8.9.2 R&D Pipeline Analysis
  • 8.9.3 Strategic Analysis
• 8.10 Schering-Plough
  • 8.10.1 Marketed Dermatological Product Portfolio
  • 8.10.2 R&D Pipeline Analysis
  • 8.10.3 Strategic Analysis
• 8.11 Sanofi-Aventis
  • 8.11.1 Marketed Dermatological Product Portfolio
  • 8.11.2 Strategies Analysis
• 8.12 Others
  • 8.12.1 Eisai
  • 8.12.2 Ipsen

Chapter 9 New Technology Developments and Strategic Analysis

• 9.1 New Technology Pipeline Developments
• 9.2 Macro-environmental Analysis
  • 9.2.1 Potential entrants
  • 9.2.2 Supplier Bargaining Power
  • 9.2.3 Consumer Bargaining Power
  • 9.2.4 Substitutes Threats
  • 9.2.5 Rivals Competitions
• 9.3 Strategic Analysis
  • 9.3.1 SWOT Analysis

Chapter 10 Conclusion

• 10.1 A Review for Current Dermatological Market
• 10.2 The Analysis for Future Dermatological Market
  • 10.2.1 Sales Performance
  • 10.2.2 Market Share
• 10.3 Strategy Analysis

List of Tables

• Table 1.1 The Sales Performance of Dermatological Markets ($M)
• Table 3.1 Acne Prevalence in the Major Seven Markets (' 000)
• Table 3.2 Marketd Topical Clindamycin Drugs in 2006
• Table 3.3 Marketed Topical Retinoid Agents in 2006
• Table 3.4 Marketed Oral Retinoid Agents in 2006
• Table 3.5 Marketed Estrogen Agents in 2006
• Table 3.6 Acne Market Performance (2003-2006)
• Table 3.7 Leading Anti-Acne Treatments in 2006
• Table 3.8 The Sales Performance of Leading Anti-Acne Treatments in ' 05/' 06
• Table 3.9 Leading Topical Anti-Acne Treatments in 2006
• Table 3.10 The Sales Performance of Leading Topical Anti-Acne Treatments in ' 05/' 06
• Table 3.11 Leading Oral Anti-Acne Treatments in 2006
• Table 3.12 The Sales Performance of Leading Anti-Acne Treatments in ' 05/' 06
• Table 3.13 Sales Forecasts of Topical Acne Treatments (' 07-' 22)
• Table 3.14 Sales Forecasts of Oral Acne Treatments (' 07-' 22)
• Table 3.15 Sales Forecasts(M) for Global Acne Market (' 07-' 22)
• Table 4.1 Psoriasis Prevalence in the Major Seven Markets (' 000)
• Table 4.2 Marketed Psoriasis Vitamin D3 Analogues in 2006
• Table 4.3 Global Anti-Psoriasis Market ($M)
• Table 4.4 Leading Psoriasis Treatments in 2006
• Table 4.5 The Sales Performance of Leading Psoriasis Treatments in 2006 ($M)
• Table 4.6 Sales Forecasts (M) of Psoriasis Treatments (2007-2022)
• Table 5.1 Bacteria Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.2 Fungal Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.3 Viral Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.4 Sales Performance of Dermatological Infective Treatments ($M)
• Table 5.5 Leading Dermatological Anti-Infective Treatments in 2006
• Table 5.6 Sales Performance of Leading Anti-Infective Treatments ($M)
• Table 5.7 Sales Forecasts of Anti-Infective Treatments (2007-2022)
• Table 6.1 Atopic Dermatitis Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 6.2 Rosacea Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 6.3 Sales Performance of Corticosteroids ($M) 2003 to 2006
• Table 6.4 Leading Corticosteroid Agents in 2006
• Table 6.5 The Sales Performance of Leading Corticosteroids ($M)
• Table 6.6 Sales Forecasts of Corticosteroids ($M) 2007-2022
• Table 6.7 Sales Performance of Other Dermatological Treatments ($M)
• Table 6.8 Leading Other Dermatological Products (2006)
• Table 6.9 Sales Performance of Leading Other Dermatological Products (2005/2006)
• Table 6.10 Sales Forecasts of Other Dermatological Treatments ($M)
• Table 7.1 Top Five Cosmetic Procedures in the US in 2006
• Table 7.2 Sales Performance of Leading Botulinum Toxin ($M)
• Table 7.3 Leading Botulinum Toxin in 2006
• Table 7.4 Sales Forecasts of Botulinum Toxin ($M) 2007-2022
• Table 8.1 Guidelines for Botox Outside of the US in 2006
• Table 8.2 GSK' s Main Dermatological Products (2006)
• Table 8.3 J&J' s Sales Performance of Marketed Products ($M)
• Table 8.4 J&J' s Leading Dermatological Products ($M)
• Table 8.5 J&J' s Dermatological Pipeline Development (2006
• Table 8.6 L' Oreal' s Marketed Dermatological Products ($M) in 2006
• Table 8.7 L' Oreal' s Leading Dermatological Products in 2006
• Table 8.8 Leo Pharma' s Market Dermatological Products ($M) in 2006
• Table 8.9 Leo Pharma' s Leading Dermatological Products ($M) in 2006
• Table 8.10 Leo Pharma' s Dermatological R&D in 2006
• Table 8.11 Novartis' Marketed Dermatological Products ($M) in 2006
• Table 8.12 Novartis' Leading Dermatological Products in 2006
• Table 8.13 Novartis' Dermatological Pipeline Developments in 2006
• Table 8.14 Roche' s Marketed Dermatological Products ($M)
• Table 8.15 Roche' s Leading Dermatological Products in 2006
• Table 8.16 Stiefel' s Marketed Dermatological Rpoducts ($M) in 2006
• Table 8.17 Stiefel' s Leading Dermatological Products in 2006
• Table 8.18 Stiefel' s Dermatological Pipeline Developments in 2006
• Table 8.19 Bayer' s Marketed Dermatological Products ($M) in 2006
• Table 8.20 Bayer' s Leading Dermatological Products in 2006
• Table 8.21 Schering-Plough' s Marketed Dermatological Treatments ($M)
• Table 8.22 Schering-Plough' s Leading Dermatological Products in 2006
• Table 8.23 Sanofi-Aventis' Marketed Dermatological Products ($M)
• Table 8.24 Sanofi-Aventis' Leading Dermatological Products in 2006
• Table 9.1 SWOT Analysis for Dermatological Market
• Table 10.1 Sales Performance of Dermatological Market ($M) 2003-2006
• Table 10.2 Sales Forecasts for Dermatological Markets ($M) 2007-2022
• Table 10.3 Market Share of Dermatological Treatments, 2006, 2012 and 2022

List of Figures

• Figure 1.1 Market Share of Dermatological Market in 2006
• Figure 1.2 Strategic Performance of Dermatological Treatments in 2006
• Figure 3.1 Market Share of Acne Treatments in 2006
• Figure 3.2 The Strategic Performance of Topical Anti-Acne Treatments in 2006
• Figure 3.3 Strategic Performance of Oral Anti-Acne Treatments in 2006
• Figure 3.4 Sales Forecasts (M) of Global Acne Market (2007-2022)
• Figure 4.1 The Factors Influencing Psoriasis Treatments
• Figure 4.2 Strategic Performance of Leading Psoriasis Treatments in 2006
• Figure 4.3 Sales Performance of Psorasis Treatments ($M)
• Figure 5.1 Sales Performance of Dermatological Anti-Infective Market ($M)
• Figure 5.2 Strategic Performance of Anti-Infective Market (2006)
• Figure 5.3 Strategic Performance of Laeding Anti-Infective Treatments in 2006
• Figure 6.1 Sales Performance of Corticosteroids ($M) 2003-2006
• Figure 6.2 Strategic Performance of Corticosteroids in 2006
• Figure 6.3 Market Share of Leading Corticosterods (2006)
• Figure 6.4 Market Share of Other Dermatological Products (2006)
• Figure 6.5 Strategic Performance of Other Dermatological Products (2006)
• Figure 6.6 Strategic Performance of Leading Other Dermatological Products (2006)
• Figure 7.1 Expenditure of Cosmetic Surgical Procedure in the US (2006)
• Figure 7.2 Expenditure of Cosmetic Non-Surgical Procedure in US (2006)
• Figure 7.3 Sales Forecasts of Botulinum Toxin ($M) 2007-2022
• Figure 8.1 Sales Share of Botox in Different Usage (06)
• Figure 8.2 Sales of Botox in Major Countries (2004-2006)
• Figure 8.3 USage of Zovirax (2006)
• Figure 8.4 Leading Products in J&J (' 06)
• Figure 8.5 L' Oreal' s Leading Products in 2006
• Figure 8.6 Leo Pharma' s Leading Products in 2006
• Figure 8.7 Novartis' Leading Dermatological Products in 2006
• Figure 8.8 Novartis' Leading Dermatological Products ($M) 2003-2006
• Figure 8.9 Roche' s Leading Dermatological Products (2006)
• Figure 8.10 Stiefel' s Leading Dermatological Products in 2006
• Figure 8.11 Bayer' s Leading Dermatological Products in 2006
• Figure 8.12 Schering-Plough' s Leading Products in 2006
• Figure 8.13 Sanofi-Aventis' Leading Dermatological Products in 2006
• Figure 9.1 The Factors Impacts Pipeline Developments
• Figure 9.2 Porter-Five-Forces Analysis for Dermatological Market
• Figure 10.1 Market Share of Dermatological Products in 2006
• Figure 10.2 Strategic Performance of Dermatological Treatments in 2006

Organisations mentioned in the report

• Agis Industries
• Alcon
• Allergan
• Altana
• American Society for Aesthetic Plastic Surgery
• Astellas
• Barr
• Bayer
• Bioglan
• BMS
• ColBar LifeScience Ltd
• Connetics/Stiefel
• Cougar Biotechnology
• DreamPharma Corporation
• Eisei Co
• Eli Lilly
• Esteve
• Eurofarma
• Expanscience
• FDA
• Fumedica
• Galderma
• Gedeon Richter
• Genentech
• GenPharm
• Graceway Pharma
• Gruenenthal
• GSK
• Idexx
• IMS
• Inamed
• Ipsen
• Johnson&Johnson
• LEO Pharma
• Loreal
• Medicis
• Merck &Co.
• Merz
• Minnesota 3M
• Mylan
• Nestle
• Novartis
• Nycomed Pharma
• Ortho
• Penederm
• Perrigo
• Pfizer
• Pieer Fabre
• Q-Med
• Ranbaxy
• Ratiopharm
• Roche
• Sanofi-Aventis
• Schering-Plough
• Shionogi
• Stiefel Labs
• Taro
• Valeant
• Warner Chilcott